GAL-3 modulates immune escape of tumor cells by targeting the survival of effector CTLs and Th1 cells, or by skewing the balance toward a Th2-type cytokine profile and/or inducing the differentiation and expansion of Tregs 59-61. Here, LGALS3 is linked to neoplasm.